期刊文献+

洛沙平合并解郁化痰安神合剂治疗精神分裂症临床观察

Clinical Observation Schizophrenia Treated by Jieyu Huatan Anshen Formula Combined with loxapine
下载PDF
导出
摘要 目的观察洛沙平合并解郁化痰安神合剂与单用洛沙平维持治疗精神分裂症的疗效及安全性。方法将90例精神分裂症患者随机分为研究组和对照组,研究组用洛沙平减半剂量合并解郁化痰安神合剂,对照组单用洛沙平维持剂量不变治疗,疗程8周。使用阳性和阴性症状量表(PANSS)、副反应量表(TESS)评定疗效和安全性。结果8周后两组患者PANSS总分及因子分与治疗前比较明显下降(P<0.01),根据PANSS减分率评定,研究组总有效率为68.8%,对照组为64.4%,两组间比较差异无统计学意义(P>0.05)。研究组与对照组的不良反应事件发生率分别为22.2%、71.1%,两组比较差异有统计学意义(P<0.01)。结论洛沙平合并解郁化痰安神合剂维持治疗精神分裂症疗效可靠,安全性高。 Objective To compare the effect and safety of Jieyu Huatan Anshen Formule (Formula for relieving stagnation,dissolving phlegm and calming the mind) combined with loxapine and loxapine used singly in the treatment of schizoph-renia.Methods Totally the 90 schizophrenia patients were randomized into a control group (n=45),treated with loxapine,and a study group (n=45),treated by Jieyu Huatan Anshen Formula combined with the half do sage of loxapine. The observation lasted 8 weeks. The therapeut iceffect and safety were evaluated by the positive and negative syndrome scale (PANSS) ,and treatment emergent symptom scale (TESS). Results After treatment,the PANSS total scores and the factor scores of both groups were significantly decreased (P〈0.01). According to the rate of PANSS total scores subtraction,total effective rate of the study group was 68.8% and of the control group 64.4% ,without sifnificant difference in both groups (P 〉0.05). The incidence of side effect of the study group and the control group was 22.2% and 71.1% respectively,there exsisted a significant difference (P0. 01). Conclusion Jieyu Huatan Anshen Formula combined with loxapine is effective and safe in the treatment of schizophrenia.
作者 原富强 娄涛
出处 《中国实用医药》 2010年第8期37-38,共2页 China Practical Medicine
关键词 精神分裂症 洛沙平 解郁化痰安神合剂 Schizophrenia Loxapine Jieyu Huatan A nshen Formula
  • 相关文献

参考文献3

二级参考文献17

  • 1王立伟,武春艳.洛沙平——非典型的抗精神病药?[J].上海精神医学,2003,15(2):121-123. 被引量:21
  • 2黄淑贞,秦英绂,王渌生,王振环,马崔,郑洪波.丁二酸洛沙平与盐酸氯丙嗪治疗精神分裂症的比较[J].中国新药杂志,1997,6(3):161-164. 被引量:20
  • 3[1]Kapur S, Zipursky RB, Jones C, et al. The D2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology.1996 Dec; 15(6): 562~566
  • 4[2]Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994 Mar;268(3) :1403~1410
  • 5[3]Singh AN, Barlas C, Singh S, et al. A neurochemieal basis for the antipsychotie activity of loxapine: interactions with dopamine D1, D2 ,D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry-Neurosci.1996 Jan; 21(1): 29~35
  • 6[4]Kapur S, Zipursky R, Remington G, et al. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry. 1997 Nov;154(11): 1525~1529
  • 7[5]William M, Glazer MD. Dose loxapine have "Atypical" properties?clinical evidence. J C lin Psychiatry. 1999 ;60 (supple 10): 42~46
  • 8[6]Peter F, Buckley, MD. The role of typical and atypical antipsychotics medication in the management of agitation and aggression. J Clin Psychiatry. 1999 ;60(supple 10): 52~60
  • 9[7]Meltzer HY, Jayathilake K. Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard - dose loxapine? J Clin Psychiatry. 1999; 60 Suppl 10: 47~51
  • 10[9]Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry. 1999; 60 Suppl 10: 20~30

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部